<DOC>
	<DOCNO>NCT00664898</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib study conduct approximately eight site Europe U.S. design evaluate safety , pharmacokinetics , activity SGN-40 combine bortezomib patient multiple myeloma relapse refractory least one prior systemic treatment regimen .</brief_summary>
	<brief_title>A Study Safety Pharmacology SGN-40 Administered Combination With Bortezomib Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age ≥ 18 year Documented pathologic diagnosis multiple myeloma relapse failed respond treatment least one prior systemic therapy ( corticosteroid monotherapy ) Measurable disease At least one prior systemic therapy singleagent corticosteroid European Union patient must prior bone marrow transplant ( autologous ) ineligible transplant If previously receive bortezomib , demonstration clinical response duration stable disease progressionfree interval ≥ 6 month start therapy If previously receive bortezomib , must recover bortezomibrelated toxicity must peripheral neuropathy score Grade ≤ 1 , accord NCI CTCAE v3.0 If applicable , completion autologous transplant ≥ 12 week prior Day 1 Discontinuation previous anticancer investigational therapy ≥ 21 day prior treatment , ≥ 90 day prior treatment previous monoclonal antibody administration Prior allogeneic bone marrow transplant Other invasive malignancy within 3 year prior Day 1 except adequately treat basal cell squamous cell skin cancer ; carcinoma situ cervix , breast , prostate ; cancer patient diseasefree ≥ 3 year Prior anaphylactic reaction human immunoglobulin administration Symptomatic hyperviscosity syndrome Active infection require parenteral antibiotic within 14 day Day 1 Major surgical procedure significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study Clinically significant cardiac dysfunction significant organ dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>anti-CD40</keyword>
	<keyword>Myeloma</keyword>
</DOC>